FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesCovid-19 Supply Chain: Managing Risk & Disruption
Topics: Conference, COVID-19, Supply Chain
Executive Summary
Members
Expanded Access: Past, Present and Future Improvements
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Position Paper
Free
Guy Disney - European Knowledge Forum Keynote Speaker 2022
Topic: Conference
Video
Members
